SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 8,126.00 |
| Book Value / Share | 7.25 |
| Price / Book | n/a |
| NCAV ($M) | -22,868.00 |
| NCAV / Share | -20.40 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.02 |
| Return on Assets (ROA) | -0.01 |
| Return on Equity (ROE) | -0.06 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.69 |
| Current Ratio | 1.02 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 12,485.00 |
| Assets | 43,479.00 |
| Liabilities | 35,353.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 15,846.00 |
| Operating Income | 2,918.00 |
| Net Income | -559.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 1,368.00 |
| Cash from Investing | 968.00 |
| Cash from Financing | -1,913.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Phoenix Holdings Ltd. | 4.83 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,157,489 | 8,409,381 | 13.76 | |
| 1,034,351 | 6,167,170 | 16.77 | |
| 1,590,400 | 7,233,697 | 21.99 | |
| 2,254,784 | 13,512,265 | 16.69 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABBV – AbbVie Inc. | ABT – Abbott Laboratories |
| ADCT – ADC Therapeutics SA | ANRO – Alto Neuroscience, Inc. |
| ANVS – Annovis Bio, Inc. |